Holen Sie sich die Stockscreener-App
1.525
4.09%
-0.065
Schlusskurs vom Vortag:
$1.59
Offen:
$1.59
24-Stunden-Volumen:
1.01M
Relative Volume:
0.97
Marktkapitalisierung:
$256.87M
Einnahmen:
$314.00K
Nettoeinkommen (Verlust:
$-40.23M
KGV:
-1.6576
EPS:
-0.92
Netto-Cashflow:
$-84.71M
1W Leistung:
+11.31%
1M Leistung:
+27.08%
6M Leistung:
-9.23%
1J Leistung:
+42.52%
1-Tages-Spanne:
$1.51
$1.60
1-Wochen-Bereich:
$1.43
$1.95
52-Wochen-Spanne:
$1.025
$2.85
Atai Life Sciences N V Stock (ATAI) Company Profile
Firmenname
Atai Life Sciences N V
Sektor
Branche
Telefon
49 89 2153 9035
Adresse
WALLSTRASSE 16, BERLIN
Vergleichen Sie ATAI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ATAI | 1.525 | 256.87M | 314.00K | -40.23M | -84.71M | -0.92 |
| VRTX | 450.45 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.61 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.16 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
| 2021-11-11 | Eingeleitet | ROTH Capital | Buy |
| 2021-10-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-09-01 | Eingeleitet | Jefferies | Buy |
| 2021-07-13 | Eingeleitet | Berenberg | Buy |
| 2021-07-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-13 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2021-07-13 | Eingeleitet | Citigroup | Buy |
| 2021-07-13 | Eingeleitet | Cowen | Outperform |
| 2021-07-13 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Atai Life Sciences N V Aktie (ATAI) Neueste Nachrichten
Atai Life Sciences stock target cut, retains buy rating on developments - Investing.com
Oxbridge Re Holdings Among 3 US Penny Stocks To Watch - Simply Wall St
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024 - TipRanks
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
atai Life Sciences Advances Psychedelic Pipeline as FDA Clears DMT Depression Treatment | ATAI Stock News - StockTitan
374Water And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Are ATAI Life Sciences N.V.’shares a good deal? - US Post News
Insider Sale Alert: ATAI Life Sciences N.V. [ATAI] – Is it Time to sell? - Knox Daily
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - StockTitan
Selling Buzz: ATAI Life Sciences N.V. [ATAI] 10% Owner ATAI Life Sciences N.V. sells 2,660,000 shares of the company - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s results reveal risk - US Post News
Maxim Group gives a Buy recommendation for ATAI Life Sciences N.V. (ATAI) - Knox Daily
ATAI Life Sciences completes acquisition of IntelGenx Corp. - Investing.com India
ATAI Life Sciences completes acquisition of IntelGenx Corp. By Investing.com - Investing.com South Africa
10% Owner ATAI Life Sciences N.V. sale 2,660,000 shares of ATAI Life Sciences N.V. [ATAI] - Knox Daily
ATAI Life Sciences N.V. (ATAI) stock analysis: A comprehensive overview - US Post News
Trading Day Review: ATAI Life Sciences N.V. (ATAI) Loses Momentum, Closing at 1.16 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: ATAI Life Sciences N.V. (ATAI) - SETE News
Maxim Group Upgrades ATAI Life Sciences N.V. (ATAI) to a Buy from a Hold - Knox Daily
Life Sciences N.V. Atai Sells 2,660,000 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock - MarketBeat
Atai Life Sciences executives sell shares valued at $16 million - Investing.com India
Deeper Dive: Understanding ATAI Life Sciences N.V. (ATAI) Through its Various Ratios - The Dwinnex
ATAI Life Sciences N.V. (ATAI) deserves closer scrutiny - US Post News
ATAI Life Sciences N.V. [ATAI] Shares Fall Approximately -7.81% Over the Year - Knox Daily
TWKS SPECIAL ALERT: Thoughtworks Shareholders Seeking More Than $4.40 Per Share Contact Julie & Holleman Regarding Sale to Apax - PR Newswire
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
T2 Biosystems Achieves Successful Defense of Patent for - GlobeNewswire
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan
Magic mushroom market set to go gangbusters, Irish researcher says - Mugglehead
ATAT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Australian Clinical Labs Shareholder Stake Shifts - TipRanks
(ATAT) Trading Advice - Stock Traders Daily
T2 Biosystems director sells shares worth $133 - Investing.com India
Atour Lifestyle Holdings Ltd ADR (ATAT) is looking forward to a strong quarter - SETE News
Atour Lifestyle Holdings Limited (NASDAQ:ATAT) Short Interest Down 8.3% in August - MarketBeat
Alzheimer’s drug developer Actinogen rattles the tin - The Australian Financial Review
Substantial Stake Acquired in Australian Clinical Labs - TipRanks
Cat defies the odds to survive after being born with two faces - MSN
ATAI Life Sciences N.V. [ATAI] See Remarks makes an insider sale of 151,303 shares worth $0.29 million. - Knox Daily
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients - GlobeNewswire
Two-faced kitten in Phetchabun leaves locals feline lottery curious - Thaiger
Monitoring ATAI Life Sciences N.V. (ATAI) after recent insider movements - Knox Daily
Market Watch Highlights: ATAI Life Sciences N.V. (ATAI) Ends on an Upturn Note at 1.24 - The Dwinnex
ATAI Life Sciences N.V. [ATAI] Insider Activity: An Update for Investors - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s stock chart: A technical perspective - US Post News
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Psychedelic Drugs Market to Grow by USD 1.37 Billion from 2024-2028, Driven by Increasing Mental Health Disorders, Report Highlights AI's Impact on the Market LandscapeTechnavio - The Malaysian Reserve
Psychedelic Stock Deep Dive: Atai Life Sciences (ATAI) (NASDAQ:ATAI) - Seeking Alpha
Finanzdaten der Atai Life Sciences N V-Aktie (ATAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):